• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Skysona

Hand scales with money and drugs
Special Reports

UPDATED: Most expensive drugs in the US in 2025

One-dose gene therapies with multimillion-dollar price tags make up the top 10 most expensive drugs in the U.S.
Zoey Becker , Kevin Dunleavy , Eric Sagonowsky , Angus Liu , Fraiser Kansteiner Aug 11, 2025 3:00am
FDA

FDA restricts bluebird's gene therapy after blood cancer reports

Aug 8, 2025 11:19am
bluebird

bluebird investors get on board with sale to Carlyle, SK Capital

May 30, 2025 11:50am
Bluebird Bio CEO snares 24 million pay package as gene therapy advance

FDA considers 'regulatory action' for bluebird's Skysona

Dec 2, 2024 11:22am
Bluebird Bio CEO snares 24 million pay package as gene therapy advance

Bluebird down 18% with slow uptake of SCD gene therapy Lyfgenia

Aug 14, 2024 12:07pm
bluebird

HHS provides unfavorable opinion on bluebird's fertility program

Jul 22, 2024 5:26pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings